SNC
TRIB

Stifel Nicolaus & Co’s Trinity Biotech TRIB Stock Holding History

Stifel Nicolaus & Co’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		$395K Hold
121
– – 0.01% 1008
2013
Q2 		$306K Buy
+121
New +$301K 0.01% 1082

Other funds holding TRIB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
AAM
ACK Asset Management Greenwich, Connecticut $801M AUM 60.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Stifel Nicolaus & Co's TRIB Position: Q3 2013 in Review

Stifel Nicolaus & Co held its Trinity Biotech (TRIB) position steady in Q3 2013 at 121 shares worth $395K. The position accounts for 0.01% of the portfolio, ranked #1008.

Stifel Nicolaus & Co first reported a position in TRIB in Q2 2013 and has held it in 2 quarters since. 69 funds tracked by Wall St. Rank hold TRIB as of Q3 2013.

  • Stifel Nicolaus & Co held 121 shares of Trinity Biotech worth $395K as of Q3 2013.
  • Stifel Nicolaus & Co left its Trinity Biotech share count unchanged in Q3 2013.
  • Trinity Biotech made up 0.01% of Stifel Nicolaus & Co's portfolio in Q3 2013, its #1008 holding.
  • Stifel Nicolaus & Co first reported a position in Trinity Biotech in Q2 2013 and has held it in 2 quarters since.
  • 69 funds tracked by Wall St. Rank held Trinity Biotech as of Q3 2013.

Based on Stifel Nicolaus & Co's 13F filing for Q3 2013, filed 13 Nov 2013.